Xiaflex 0.9 MG vials
Ended Awarded
- Contract number
- SPE2DB26FX1LC
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,454
Award facts
- Contract value 100% obligated
- $16,454.48 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,454.48 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xiaflex 0.9 mg vials. The delivery order, issued on November 5, 2025, with an ultimate completion date of November 28, 2025, carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group was selected as the awardee under its Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors.
The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, features a $499,999,999 ceiling value and extends through December 31, 2036, encompassing a 30-month base period with three 30-month option periods. This vehicle authorizes the Defense Logistics Agency to issue delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support Department of Defense healthcare operations globally. The current delivery order for Xiaflex represents one of numerous orders issued under this prime vendor contract, positioning DMS Pharmaceutical Group as a critical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DB26FX1LC?
SPE2DB26FX1LC was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 5, 2025.
How much is contract SPE2DB26FX1LC worth?
The government has obligated $16,454 on SPE2DB26FX1LC.
Is contract SPE2DB26FX1LC an order under another contract?
Yes. SPE2DB26FX1LC is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB26FX1LC competed?
The extent of competition for SPE2DB26FX1LC was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award